COVID-19 Outbreak Update #16 Remdesivir

On May 10, 2020, NH DHHS issued health alert COVID-19 update #16 related to remdesivir.

NH DPHS Health AlertsKey Points and Recommendations

  • The NH Department of Health and Human Services (DHHS) is receiving a small supply of remdesivir from the federal government and will distribute it proportionally (based on COVID-19 case counts) to hospitals that affirm willingness and capacity to manage this medication under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). 
  • The EUA permits the use of remdesivir for the treatment of hospitalized adult and pediatric patients with severe COVID-19. 
  • Remdesivir is an investigational direct acting antiviral drug that inhibits viral RNA synthesis and has demonstrated in-vitro activity against SARS-CoV-2 with preliminary data showing that remdesivir may shorten the time to recovery and possibly decrease mortality in adult patients hospitalized with COVID-19. 
  • Clinicians managing patients for whom remdesivir is appropriate under the FDA EUA, and who have access to remdesivir through their hospital pharmacies, must review the following information and requirements before treating patients: 
  • The Fact Sheet for health care providers contains important information about who may receive remdesivir under the FDA EUA, preparation and storage information, dosing and administration instructions, and other specific instructions for health care providers and mandatory requirements for administration. 
  • Initial supply of remdesivir will be limited, so hospitals and clinicians should decide who will be prioritized for remdesivir based on their patients and current supply. DHHS will notify participating hospitals immediately on receipt of drug.

Read the full DHHS alert